Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Graft vs Host Disease 1

Interventions

trametinib 4dabrafenib 4encorafenib 3Oxaliplatin 3zolbetuximab 2selpercatinib 2pembrolizumab 2lenvatinib 2larotrectinib 2dostarlimab 2binimetinib 2Leucovorin 2Fulvestrant 2Fluorouracil 2Cetuximab 2Capecitabine 2trastuzumab deruxtecan 1tepotinib 1telisotuzumab vedotin 1ribociclib 1repotrectinib 1relatlimab 1pralsetinib 1pegaspargase 1niraparib 1blinatumomab 1avelumab 1asparaginase erwinia chrysanthemi recombinant 1adagrasib 1Vemurafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Neoplasms × Abatacept × Clear all
NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Boston Children's Hospital

Phase 2 Completed
186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡